Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus NIKKI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus NIKKI.
ASHLYNA vs NIKKI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
NIKKI is a combination oral contraceptive containing ethinyl estradiol and drospirenone. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropin release, thereby inhibiting ovulation.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life: 12-15 hours; clinical context: allows once-daily dosing; steady-state reached in ~3 days
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Renal: 50% (20% unchanged, 30% as metabolites); Fecal: 40%; Biliary: 10%
Category C
Category C
Contraceptive
Contraceptive